The cystic fibrosis transmembrane conductance regulator (CFTR) is a significant modulator of cerebrovascular reactivity; the loss of CFTR function enhances myogenic vasoconstriction.
decline has emerged as a major clinical concern for patients with heart failure (HF) and stroke. Therefore, improving cognitive function will positively affect the primary disease, in addition to yielding both personal and socioeconomic benefits.
Our recent work focused on 2 etiologically distinct pathologies that are strongly associated with cognitive impairment: heart failure (HF) and subarachnoid hemorrhage (SAH). Clinically, the prevalence of earlyonset cognitive impairment in patients with HF ranges from 25% to 75% (2) ; the prevalence in SAH is estimated to be 73% (3) . Experimental mouse models emulate several key features of these diseases, including reduced cerebral blood flow (CBF) and compromised neurologic function (2, (4) (5) (6) (7) . Despite their distinct etiologies, a common microvascular mechanism contributes to the reduced cerebral perfusion observed in experimental HF and SAH: an increase in cerebral artery myogenic reactivity, and hence, resistance to blood flow (5, 6, 8) .
At the molecular level, both pathologies induce robust tumor necrosis factor (TNF) expression within the cerebral artery wall; this smooth muscle cellÀlocalized TNF acts by an autocrine and/or paracrine mechanism to increase the bioavailability of sphingosine-1-phosphate (S1P), a pro-constrictive mediator that augments myogenic reactivity (4, 6, 8) .
Specifically, TNF signaling in cerebral arteries stimulates S1P production and concomitantly downregulates a critical negative regulator of S1P signaling, the cystic fibrosis transmembrane conductance regulator (CFTR) (8) (9) (10) . CFTR acts as a negative regulator, because it sequesters S1P from its receptors and transports it across the plasma membrane for intracellular degradation (8) . Therefore, reduced CFTR activity increases S1P bioavailability and represents a key component of the pathological augmentation of cerebral artery myogenic tone in HF and SAH (4, 6, 8) .
Antagonizing TNF signaling with etanercept successfully abolishes the pathological augmentation of cerebrovascular vasoconstriction in HF and SAH, and thus, improves cerebral perfusion (4, 6, 8) .
This intervention also reduces neuronal injury and improves neuro-functional outcome (5, 6) , which strongly suggests that cerebral hypoperfusion contributes to the neurologic injury observed in these 2 models. However, as a clinical intervention, etanercept carries significant adverse effect risks stemming from immunosuppression (11) and potential effects on blood pressure control (12).
Based on our previous observations that 1) cerebral artery CFTR expression is reduced in HF and SAH (6, 8) ; and 2) antagonizing TNF signaling in these pathologies normalizes CFTR expression concomitantly with vascular reactivity (6, 8) , we propose that CFTR represents a good therapeutic target for improving perturbed microvascular reactivity in HF and SAH and hence, CBF and cognitive decline. Food and Drug AdministrationÀapproved medications that increase CFTR expression and/or activity are available (13) , and they are not generally associated with adverse side effects.
METHODS
The present investigation acquired the CFTR corrector therapeutic "C18" and the anti-human CFTR antibody (designated "596") through the Cystic Quebec, Canada). Male mice homozygous for the DF508 CFTR mutation (CFTR tm1EUR ; designated "DF508" in the present study) (14) , CFTR gene deletion (CFTR tm1Unc ; designated CFTR À/À ) and the complimentary wild-type control littermates were obtained from an established colony at the Hospital for Sick Children (Toronto, Ontario, Canada) (all CFTR À/À , CFTR DF508 , and wild-type littermates are mixed strains). Phenotype details for these CFTR mutant mice can be found in the Supplemental Appendix. All mice were housed under a standard 14 h/10 h lightÀdark cycle, fed normal chow, and had access to water ad libitum. MYOCARDIAL INFARCTION. HF was induced by surgical ligation of the left anterior descending coro-closed, and the mice were extubated upon spontaneous respiration. All experimental measurements in the HF model were conducted at or after 6 weeks post-infarction. Our previous work demonstrated that the cardiac injury is stable after 6 weeks, and thus, treatments do not alter and/or improve cardiac function (4) . This allowed us to unambiguously attribute improvements in CBF in this model to a cerebrovascular mechanism.
INDUCTION OF SAH. We used a well-characterized model of experimental SAH (6) . Briefly, each mouse was anesthetized (isoflurane), and its head was fixed in a stereotactic frame; a 7-mm incision was made along the midline of the anterior scalp and a 0.9-mm hole drilled into the skull 4.5-mm anterior to the bregma. A spinal needle was advanced to the chiasmatic cistern; 80 ml of arterial blood was injected into the intracranial space over 10 s. The injected blood was obtained from a separate wild-type donor mouse (via cardiac puncture) immediately before injection and did not contain anticoagulants. Following injection, the scalp incision was closed. Buprenorphine (0.05 mg/kg; 0.5 to 1.0 ml volume) was administered twice a day for 2 days (initiated immediately following the SAH surgical procedure). Shamoperated animals underwent an identical surgical procedure, with sterile saline injected instead of blood. All experimental measurements in the SAH model were conducted at 2 days post-SAH induction.
Our previous work demonstrated that SAH maximally augments myogenic tone at this time point; reductions in CBF, neuronal injury, and compromised neurologic function are also evident at this time (6) .
ISOLATION AND FUNCTIONAL ASSESSMENT OF RESISTANCE ARTERIES. Mouse olfactory (a first branch of the anterior cerebral artery) and posterior cerebral arteries (PCAs) were carefully dissected, cannulated onto micropipettes, stretched to their in vivo lengths, and pressurized to 45 mm Hg, as previously described (4, 6) . Mouse skeletal muscle resistance arteries were dissected from the cremaster muscle, cannulated, and pressurized to 60 mm Hg.
All functional experiments were conducted in 3-morpholinopropanesulfonic acid (MOPS) buffered saline at 37 o C with no perfusion. Vasomotor responses to phenylephrine (5 mmol/l for PCAs, 10 mmol/l for cremaster skeletal muscle arteries) provided an assessment of vessel viability at the beginning and end of each experiment. Arteries that failed to show $25% constriction to phenylephrine were excluded. Myogenic responses were elicited by stepwise 20 mm Hg increases in transmural pressure from 20 to 80 mm Hg (olfactory arteries) or 100 mm Hg (PCAs and cremaster skeletal muscle resistance arteries). At each pressure step, vessel diameter (dia active ) was measured once a steady state was reached (5 min (tone active À tone rest , where tone active is the tone at given phenylephrine concentration and tone rest is the tone immediately before stimulation), the WT and CFTR DF508 phenylephrine doseÀresponse relationships are virtually identical. Mean maximal vessel diameters at 45 mm Hg (dia max ) are: CFTR DF508 : 186 AE 2 mm; n ¼ 6 from 4 mice, and WT: 169 AE 8 mm; n ¼ 5 from 3 mice (t-test: p ¼ NS for dia max ).
CFTR Therapeutics Normalize Cerebral Perfusion
(D) Magnetic resonance imaging was used to measure cerebral blood flow in predefined forebrain cortical regions. Representative perfusion maps from WT and CFTR DF508 mouse forebrains are shown. Cerebral blood flow (CBF) is significantly lower in CFTR DF508 mice (n ¼ 10), relative to WT littermates (n ¼ 11); however, neither (E) cardiac output (n ¼ 5 for both groups) nor (F) total peripheral resistance (n ¼ 5 for both groups) differed between the 2 genotypes. (G) In WT mice, CFTR mRNA expression is significantly higher in PCAs (n ¼ 5), relative to cremaster skeletal muscle arteries (Cre) (n ¼ 6). Lidington et al.
FIGURE 2 C18 increases WT CFTR Protein Expression and Function by a Proteostatic Mechanism
(A) Cerebral arteries isolated from naïve mice treated with C18 (3 mg/kg intraperitoneally daily for 2 days; n ¼ 5) have higher CFTR protein expression than arteries collected from vehicle control (Con) mice (n ¼ 5). (B) C18 does not influence cerebral artery CFTR mRNA expression (Con: n ¼ 6; C18: n ¼ 5). (C) C18 (6 mmol/l; 24 h) increases CFTR protein expression in baby hamster kidney fibroblast cells stably expressing human CFTR (n ¼ 12 for both groups). (D) C18 does not influence CFTR mRNA expression in this system (n ¼ 6 for both groups). (E) Tumor necrosis factor (TNF) (10 ng/ml for 48 h) downregulates CFTR protein expression in mesenteric artery primary vascular smooth muscle cells (Con: n ¼ 8; TNF: n ¼ 8); co-incubating TNF with C18 (6 mmol/l; 24 h) following 24 h TNF incubation (i.e., 48 h TNF þ 24 h C18) fully restores CFTR protein expression (n ¼ 7). The restoration of CFTR protein expression in vascular smooth muscle cells correlates with the normalization of attenuated (F) Fluorescein isothiocyanate-labeled sphingosine-1-phosphate (FITC-S1P) uptake (measured as an increase in fluorescence intensity at 525 nm by a standard fluorescence-activated cell sorting analysis technique; Con: n ¼ 7; TNF: n ¼ 10; TNFþC18: n ¼ 6) and (G) forskolin-stimulated iodide efflux (Con: n ¼ 7; TNF: n ¼ 6; TNFþC18: n ¼ 6). All data are mean AE SEM. In (A to D), *p < 0.05 for an unpaired comparison with a t-test; in (E to G), *p < 0.05 for unpaired comparisons to the Con mice with a 1-way analysis of variance and Tukey's post hoc test. Other abbreviation as in Figure 1 . The T 2 mapping acquisition generated quantitative T 2 maps in 9 contiguous 2dimensional axial slices, with 1 mm thickness, covering the volume from the fore-brain through to the hind-brain. T 2 maps were generated from Representative quantitative T 2 maps that assess brain water content as T 2 relaxation times in magnetic resonance images. A total of 9 T 2 maps were assessed per mouse, which cover the fore-, mid-, and hind-brain regions. The representative images display slices from the (left) fore-, (FITC-S1P) uptake, and iodide efflux measurements (6, 8, 16) . Specific details are provided in the Supplemental Appendix.
FLUORESCENT IMMUNOHISTOCHEMISTRY AND
FLUORO-JADE STAINING. Brains were cleared of blood and fixed via aortic perfusion with 4% paraformaldehyde; the brains were then dissected, and Maryland, USA), as previously described (5 We used a wellestablished novel object recognition task to evaluate rhino-cortical nonspatial memory, as previously described (5, 17) . Briefly, habituated mice were exposed to 2 identical objects for 5 min. After a 5-min delay, 1 of the original objects was replaced with a novel object, and the mice were retested. (18, 19) . Nevertheless, CFTR mutant mice in general, and CFTR À/À mice in particular, are known to adversely react to stress (18) . In our hands, CFTR À/À mice were extremely sensitive to experimental stressors, which did not permit accurate and reproducible echocardiography and/or CBF measurements.
CFTR DF508 mice, which have minimal cell surface CFTR expression and activity (14), were more stable.
This underpinned our strategic decision to use CFTR DF508 mice for relating cerebral artery myogenic tone to hemodynamic parameters in a loss of function phenotype.
We assessed vasomotor reactivity in PCAs to directly compare the CFTR DF508 phenotype to our previously published characterization of PCA responses from CFTR knockout mice (8) . As expected, PCAs from CFTR DF508 mice displayed augmented myogenic tone, relative to wild-type littermates ( Figure 1A) ; the magnitude of the augmentation was qualitatively similar to that found for CFTR À/À mice (8) . Phenylephrine responses displayed an upward shift due to the enhanced myogenic tone ( Figure 1B) ; however, the EC 50 values were not different (log EC 50 wild type: À5.83 AE 0.21; n ¼ 5 from 3 mice; log EC 50 CFTR DF508 : À6.00 AE 0.04; n ¼ 6 from 4 mice;
Student's t-test: p ¼ NS), and the difference between the curves was eliminated by correcting for the difference in basal tone (i.e., myogenic tone at 45 mm Hg) ( Figure 1C) . Therefore, the DF508 mutation augmented myogenic responsiveness, but did not alter general contractility. CBF was significantly lower in CFTR DF508 mice ( Figure 1D) ; however, neither cardiac output ( Figure 1E ) nor total peripheral resistance (TPR) ( Figure 1F) were affected by the mutation (additional hemodynamic parameters are listed in Supplemental Table 1 ). Based on these observations, the cerebral perfusion deficit was clearly vascular in origin.
The CFTR DF508 mutation did not change TPR, indicating that not all vascular beds were subject to CFTR- We first confirmed that C18 is capable of increasing both mouse and human CFTR expression. Cerebral arteries isolated from naïve mice injected with C18
(3 mg/kg intraperioneally daily for 2 days) displayed higher CFTR protein expression levels, relative to vehicle-treated control mice (Figure 2A) ; CFTR mRNA expression was not affected by C18 ( Figure 2B) . To confirm C18's effect on human CFTR, we used a heterologous expression system of baby hamster kidney fibroblast cells that stably expressed a human CFTR construct. C18 treatment (6 mmol/l; 24 h) more than doubled CFTR protein expression in baby hamster kidney fibroblast cells ( Figure 2C) , but had no effect on CFTR mRNA expression in this system ( Figure 2D) . Collectively, the data are consistent with previous observations that C18 exerts direct stabilizing effects on CFTR protein expression (21) and demonstrates its efficacy against both murine and human CFTR.
We next assessed whether C18 treatment increases CFTR abundance in a cell culture setting that modeled the relevant pathophysiological mechanisms and cellular environment. As we previously (Figure 2E) . As expected, the decline in CFTR expression correlated with attenuated FITC-S1P uptake [i.e., a CFTR-dependent process (8)] ( Figure 2F) and forskolin-stimulated iodide efflux [i.e., a classical measure of CFTR activity (16)] ( Figure 2G) . C18 treatment (6 mmol/l; 24 h co-incubation with 10 ng/ml TNF following 24-h incubation with 10 ng/ml TNF) reversed the decline in CFTR expression ( Figure 2E) and fully restored FITC-S1P uptake ( Figure 2F ) and iodide efflux ( Figure 2G) . These results aligned with our prediction that under conditions in which CFTR is downregulated, C18's proteostatic effect increases total CFTR expression and restores its activity.
C18 TREATMENT RECTIFIES DEFICIENT CBF IN HF.
As previously documented by Meissner et al. (8) , the induction of HF stimulated a significant reduction in cerebral artery CFTR protein expression ( Figure 3A) that coincided with a marked augmentation in PCA myogenic tone ( Figure 3B) . As predicted by the data in Figure 2 , C18 treatment in vivo (3 mg/kg intraperioneally daily for 2 days) restored CFTR expression in cerebral arteries isolated from mice with HF ( Figure 3A) and concomitantly normalized PCA myogenic tone ( Figure 3B) . Figure 4) . C18 treatment did not affect PCA myogenic tone or phenylephrine responses in sham-operated mice (Supplemental Figure 5 ). Using PCAs isolated from CFTR knockout mice, we confirmed that C18 mediates its attenuating Figure 3C) ; phenylephrine responses were not affected by C18 treatment (Supplemental Figure 6) .
At the systemic level, the induction of HF significantly reduced cardiac output relative to shamoperated control mice ( Figure 3D ; measured at 6 weeks post-infarction). TPR increased as a compensatory response ( Figure 3E) to prevent a large reduction in MAP ( Figure 3F) (4,8) . Despite the relatively small reduction in MAP, CBF was markedly reduced ( Figure 3G ). C18 treatment in vivo restored CBF in mice with HF ( Figure 3G) , correlating to the normalization of PCA myogenic tone ( Figure 3B ). C18 did not ameliorate the cardiac injury induced by the left anterior descending coronary artery ligation procedure (Supplemental Table 2 ). Therefore, the improvement in CBF can be unambiguously attributed to a vascular mechanism. Furthermore, because C18 had no effect on TPR or MAP (Figure 3) , the C18-mediated restoration of CBF had to be a localized microvascular effect that was independent of changes to systemic hemodynamic parameters. This therapeutic profile aligns well with our previously described etanercept intervention (4) .
In addition to maintaining constant perfusion when systemic pressure fluctuates, the myogenic response also protects fragile capillary beds from damaging pressure levels (22) and maintains capillary hydrostatic pressure at levels that minimize edema formation (23) . In this context, therapeutically reducing cerebral artery myogenic tone, even from the augmented level that occurs in HF, could potentially cause the counter-productive side effect of cerebral edema formation. Therefore, we used noninvasive imaging for edema to confirm that neither HF nor C18 treatment in the context of HF induced evident edema in any region of the brain (Figure 4) . and Supplemental Table 3 ). As shown in Figure 5C and summarized in Supplemental Table 3 , HF did not affect the number of dendrite intersections.
Because apical and basal dendrites can be differentially affected by stressors (24), we conducted a subanalysis to confirm that neither apical nor basal dendrite intersection morphology was affected (Supplemental Figure 7 ; Supplemental Table 3 ).
However, our analysis demonstrated the presence of dendrite atrophy (i.e., a 22% reduction in dendrite length ( Figures 5C and 5D ) that was present in both apical (24% reduction) and basal (20% reduction) dendrites (Supplemental Figure 7) . HF also reduced basal dendritic spine density in the distal regions of the dendrite (60 to 100 mm from the soma) ( Figure 5E and 5F); apical dendritic spine density was not significantly altered (Supplemental Figure 8 ). C18treated HF mice (3 mg/kg intraperioneally daily for 2 weeks) did not display dendrite atrophy or a reduction in dendritic spine density ( Figure 5 , Supplemental Table 3 ).
The altered cortical neuron morphology in HF mice correlated with impaired rhino-corticalÀdependent, short-term retention of object familiarity ( Figure 5G) ; this impairment was not present in C18-treated HF mice. Longitudinal pre-treatment (i.e., at 10 weeks post-infarction) and post-treatment analyses of the same vehicle-and C18-treated HF mice confirmed that C18 reversed the impairment caused by HF ( Figure 5H) . Our previous work demonstrated that SAH has a similar cerebrovascular phenotype as HF, in that 1) cerebral artery CFTR protein expression is reduced; 2) cerebral artery myogenic tone is augmented; and 3) cerebral perfusion is reduced (6) . As in HF (Figure 3) , C18 treatment in vivo (3 mg/kg intraperioneally daily for 2 days) restored CFTR expression in cerebral arteries from mice with SAH ( Figure 6A) and (Figure 7) . Lumacaftor did not affect phenylephrine responsiveness (Supplemental Figure 12) and consequently, the EC 50 values were not different To increase brain perfusion, cerebrovascular resistance must decrease in relation to TPR. We therefore compared the role that CFTR plays in cerebral arteries to skeletal muscle resistance arteries.
We selected skeletal muscle resistance arteries for this comparison, because this vascular bed forms the body's largest circulatory network (40% of body mass is skeletal muscle); therefore, it is a prominent determinant of TPR. Our comparisons of 1) CFTR inhibition in cerebral and skeletal muscle resistance arteries, and 2) TPR measurements in CFTR mutant and wild-type mice indicated that CFTR's vascular effects do not appreciably influence MAP. This is presumably explained by the observed differences in CFTR expression across these vascular beds: skeletal muscle resistance arteries have 10-fold lower CFTR expression than do cerebral arteries. Therefore, CFTR therapeutics should exhibit similarly restricted effects. CFTR corrector treatment increases cerebral perfusion without affecting TPR. This specific effect is highly advantageous because the lack of a direct effect on peripheral resistance increases the likelihood that the intervention can be added to prescribed blood pressure management practices that would already be in place.
The myogenic response, which continuously matches vascular resistance to the prevalent transmural pressure (25, 26) , is the functional basis of CBF autoregulation. In addition to dictating cerebral perfusion through its autoregulatory function, the myogenic response also maintains capillary pressures at levels that minimize damage and edema formation (22, 23) . Therefore, reducing myogenic reactivity has the potential to induce edema formation by permitting additional pressure to enter the capillary beds.
On a related aspect, because S1P prominently regulates bloodÀbrain barrier permeability (27) Restoring normal myogenic reactivity in cerebral arteries represents a significant advantage over current strategies.
TRANSLATIONAL OUTLOOK: These data provide strong proof of principle for clinically assessing whether CFTR therapeutics improve cerebral perfusion in patients with HF and SAH. 
